Abstract
Treating Alzheimers disease (AD) is one of todays biggest unmet medical needs. The drugs currently available transiently relieve some symptoms but have no significant effects on the progression of the disease. Progress in the past decade suggests that the amyloidogenesis of the inactive monomeric amyloid β peptide (Aβ) into a subset of toxic Aβ polymers is responsible for neurodegeneration in AD. Not all forms of Aβ aggregates are damaging, for there are patients whose brains accumulated large amounts of Aβ in the form of plaques, but they had no obvious neurodegeneration and symptoms of dementia. Since Aβ can polymerize into many types of polymers or aggregates, the form of Aβ that induces neurodegeneration in AD, defined here as bioactive Aβ, is not clear. Preventing the formation of bioactive Aβ or inactivating previously formed bioactive Aβ is a promising approach for treating AD. This review describes our efforts to develop a cell-based assay for detecting bioactive Aβ, to verify the concept of bioactive Aβ in an animal model of AD and in post mortem brain tissue from AD patients, and to use this assay to screen for drugs that can inactivate bioactive Aβ. These studies show the proof in principle that inactivating bioactive Aβ is a promising approach to treat AD. Several promising compounds that can inactivate bioactive Aβ species are also described.
Keywords: Alzheimer's disease, amyloid β peptide, amyloidogenesis, bioactive amyloid species, MTT, drug screening
Current Alzheimer Research
Title: Treating Alzheimers Disease by Inactivating Bioactive Amyloid β Peptide
Volume: 3 Issue: 2
Author(s): Yuanbin Liu and David Schubert
Affiliation:
Keywords: Alzheimer's disease, amyloid β peptide, amyloidogenesis, bioactive amyloid species, MTT, drug screening
Abstract: Treating Alzheimers disease (AD) is one of todays biggest unmet medical needs. The drugs currently available transiently relieve some symptoms but have no significant effects on the progression of the disease. Progress in the past decade suggests that the amyloidogenesis of the inactive monomeric amyloid β peptide (Aβ) into a subset of toxic Aβ polymers is responsible for neurodegeneration in AD. Not all forms of Aβ aggregates are damaging, for there are patients whose brains accumulated large amounts of Aβ in the form of plaques, but they had no obvious neurodegeneration and symptoms of dementia. Since Aβ can polymerize into many types of polymers or aggregates, the form of Aβ that induces neurodegeneration in AD, defined here as bioactive Aβ, is not clear. Preventing the formation of bioactive Aβ or inactivating previously formed bioactive Aβ is a promising approach for treating AD. This review describes our efforts to develop a cell-based assay for detecting bioactive Aβ, to verify the concept of bioactive Aβ in an animal model of AD and in post mortem brain tissue from AD patients, and to use this assay to screen for drugs that can inactivate bioactive Aβ. These studies show the proof in principle that inactivating bioactive Aβ is a promising approach to treat AD. Several promising compounds that can inactivate bioactive Aβ species are also described.
Export Options
About this article
Cite this article as:
Liu Yuanbin and Schubert David, Treating Alzheimers Disease by Inactivating Bioactive Amyloid β Peptide, Current Alzheimer Research 2006; 3 (2) . https://dx.doi.org/10.2174/156720506776383077
DOI https://dx.doi.org/10.2174/156720506776383077 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Age-Related Inflammation: the Contribution of Different Organs, Tissues and Systems. How to Face it for Therapeutic Approaches
Current Pharmaceutical Design Antidepressant-Like Activity of Fish Oil, with and Without Fluoxetine, in Two Behavioral Despair Paradigms in Experimental Mice
Current Pharmacogenomics and Personalized Medicine Transient Receptor Potential (TRP) Cation Channels in Diabetes
Current Topics in Medicinal Chemistry Network Pharmacology of Ayurveda Formulation <i>Triphala</i> with Special Reference to Anti-Cancer Property
Combinatorial Chemistry & High Throughput Screening Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview
Current Alzheimer Research VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward
Current Alzheimer Research Editorial (Thematic Issue: Medicinal Chemistry: Neurological and Endocrinological Disorders)
Medicinal Chemistry Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review
Current Topics in Medicinal Chemistry Multiple Roles for Chemokines in the Pathogenesis of SIV Infection
Current HIV Research The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders
Current Topics in Medicinal Chemistry MRI Abnormalities Associated with Mild Cognitive Impairments of Vascular (VMCI) Versus Neurodegenerative (NMCI) Types Prodromal for Vascular and Alzheimers Dementias
Current Alzheimer Research The Prevalence and Progression of Arterial Calcification in Patients with End-Stage Renal Disease
Vascular Disease Prevention (Discontinued) Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Infective Proteins: The Prion Puzzle
Current Protein & Peptide Science Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimer’s Disease
Current Medicinal Chemistry Anti-Copper Therapies in Alzheimers Disease: New Concepts
Recent Patents on CNS Drug Discovery (Discontinued) Medical Expert Systems
Current Bioinformatics Tubulin-Independent Tau in Alzheimer’s Disease and Cancer: Implications for Disease Pathogenesis and Treatment
Current Alzheimer Research Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research